Want to see BCPC full AI Analyst Report?
BCPC Stock Chart & Stats
$177.66
$0.69(0.44%)
At close: 4:00 PM EST
$177.66
$0.69(0.44%)
Day’s Range― - ―
52-Week Range$139.17 - $183.90
Previous CloseN/A
Volume32.16K
Average Volume (3M)250.68K
Market Cap
$5.33B
Enterprise Value$5.39B
Total Cash (Recent Filing)$72.87M
Total Debt (Recent Filing)$184.71M
Price to Earnings (P/E)33.4
Beta0.42
Next Earnings
Jul 24, 2026EPS Estimate
1.28Next Dividend Ex-DateN/A
Dividend Yield0.61%
Share Statistics
EPS (TTM)4.90
Shares Outstanding32,129,837
10 Day Avg. Volume294,460
30 Day Avg. Volume250,683
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)3.98
Price to Sales (P/S)4.82
P/FCF Ratio28.89
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue5.10
Enterprise Value/Gross Profit14.06
Enterprise Value/Ebitda19.93
Forecast
1Y Price Target
$212.00Price Target Upside19.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)5.23
Revenue Forecast (FY)$1.11B
Bulls Say, Bears Say
Bulls Say
Sustained Margin Expansion And ProfitabilityConsistent quarter-to-quarter EBITDA growth and expanding margins reflect durable operational improvements: pricing, mix toward higher-margin products, and manufacturing efficiencies. This track record supports sustained cash flow generation and resilience through cyclical demand shifts over months.
Conservative Balance Sheet And Strong Cash GenerationLow debt levels and operating cash consistently above reported earnings provide financial flexibility for capex, M&A, and working-capital needs. Strong cash conversion and modest net leverage reduce refinancing and solvency risk while enabling strategic investments over the next several quarters.
Branded-ingredient Portfolio With Clinical SupportA growing branded portfolio backed by clinical evidence strengthens differentiation and pricing power in Human Nutrition. Branded products command higher margins and support expansion into larger adult-cognition and health end markets, delivering multi-quarter revenue and margin durability.
Bears Say
Petrochemical-driven Input-cost Inflation RiskExposure to petrochemical-linked raw materials creates a structural vulnerability: input-cost spikes can persist and pass-through lags to customers may compress margins. For a materials supplier, sustained feedstock inflation can erode profitability until pricing or procurement mitigations take effect.
Rising Operating Expenses From Growth InvestmentsHigher SG&A and investment spending to support geographic expansion and commercial teams can structurally lift the cost base. If ramp benefits are slower than planned, margin pressure could persist for quarters while the company realizes returns from these investments.
Historically Choppy Revenue Growth TrajectoryIntermittent revenue volatility across years indicates exposure to cyclical end markets and uneven demand drivers. That makes medium-term topline predictability and investment payback less certain, risking uneven margin recovery and variable free cash flow across quarters.
Balchem News
BCPC FAQ
What was Balchem’s price range in the past 12 months?
Balchem lowest stock price was $139.17 and its highest was $183.90 in the past 12 months.
What is Balchem’s market cap?
Balchem’s market cap is $5.33B.
When is Balchem’s upcoming earnings report date?
Balchem’s upcoming earnings report date is Jul 24, 2026 which is in 14 days.
How were Balchem’s earnings last quarter?
Balchem released its earnings results on Apr 30, 2026. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.245 by $0.005.
Is Balchem overvalued?
According to Wall Street analysts Balchem’s price is currently Undervalued.
Does Balchem pay dividends?
Balchem pays a Annually dividend of $0.96 which represents an annual dividend yield of 0.61%. See more information on Balchem dividends here
What is Balchem’s EPS estimate?
Balchem’s EPS estimate is 1.28.
How many shares outstanding does Balchem have?
Balchem has 32,129,837 shares outstanding.
What happened to Balchem’s price movement after its last earnings report?
Balchem reported an EPS of $1.25 in its last earnings report, beating expectations of $1.245. Following the earnings report the stock price went down -6.756%.
Which hedge fund is a major shareholder of Balchem?
Currently, no hedge funds are holding shares in BCPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Balchem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$212.00 (19.33% Upside)
$212.00 (19.33% Upside)
Blogger Sentiment
Bullish
BCPC Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 8.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.23%
12-Months-Change
Fundamentals
Return on Equity
12.38%
Trailing 12-Months
Asset Growth
4.71%
Trailing 12-Months
Company Description
Balchem
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
BCPC Company Deck
BCPC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple record financial metrics (revenue, adjusted EBITDA, adjusted EPS, gross margin dollars) and showcased broad-based growth across all three segments, strong cash generation, improved margins, sustainability achievements, and promising branded-ingredient progress (notably Vidacholine). Headwinds include emerging petrochemical-driven inflation, higher operating expenses tied to growth investments, and geopolitical-related supply-chain/freight risk that could cause modest margin compression in the near term. Overall, the positive operational and financial momentum, coupled with manageable leverage and clear strategic initiatives, outweigh the noted risks.View all BCPC earnings summariesBCPC Stock 12 Month Forecast
Average Price Target
$212.00
▲(19.33% Upside)
Technical Analysis
Ownership Overview
0.67% Insiders
29.42% Mutual Funds
1.92% Other Institutional Investors
39.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---